Inhaled SalmeterolA Review of its Efficacy in Chronic Obstructive Pulmonary Disease

[71] Piccolo A(1994)Efficacy of regular inhaled salmeterol on lung function and symptoms in patients with chronic obstructive pulmonary disease Eur Respir J 7 725-94

[72] Patakas D(2001)Using simple and relative difference to interpret changes in health-related quality-of-life scores for salmeterol, ipratropium, and placebo Chest 119 1034-6

[73] Andreadis D(2000)Evaluation of the ATS and ERS definitions of reversibility in COPD patients treated with salmeterol 50mcg bid Am J Respir Crit Care Med 161 A489-15

[74] Mavrofridis E(2000)Salmeterol is effective bronchodilator therapy for all stages of COPD Eur Respir J 16 56s-undefined

[75] Matera MG(2000)Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD Am J Respir Crit Care Med 161 A407-undefined

[76] Caputi M(1996)Determinants of different dimensions of disease severity in asthma and COPD. Pulmonary function and health-related quality of life J Clin Epidemiol 49 247-undefined

[77] Cazzola M(1998)Salmeterol xinafoate improves lung function and provides more symptom-free nights in chronic obstructive pulmonary disease (COPD) at marginal costs Thorax 53 558-undefined

[78] Cazzola M(1997)Economic evaluation of salmeterol xinafoate in chronic obstructive pulmonary disease (COPD) demonstrating improved outcomes and health status JAMA 277 246-undefined

[79] Matera MG(1994)A cost analysis of salmeterol xinafoate (Serevent) versus ipratropium bromide (Atrovent) for the treatment of COPD JAMA 272 1497-undefined

[80] Di Perna F(1992)Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients Chest 102 1384-undefined

[71] Piccolo A(1994)Efficacy of regular inhaled salmeterol on lung function and symptoms in patients with chronic obstructive pulmonary disease Eur Respir J 7 725-94

[72] Patakas D(2001)Using simple and relative difference to interpret changes in health-related quality-of-life scores for salmeterol, ipratropium, and placebo Chest 119 1034-6

[73] Andreadis D(2000)Evaluation of the ATS and ERS definitions of reversibility in COPD patients treated with salmeterol 50mcg bid Am J Respir Crit Care Med 161 A489-15

[74] Mavrofridis E(2000)Salmeterol is effective bronchodilator therapy for all stages of COPD Eur Respir J 16 56s-undefined

[75] Matera MG(2000)Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD Am J Respir Crit Care Med 161 A407-undefined

[76] Caputi M(1996)Determinants of different dimensions of disease severity in asthma and COPD. Pulmonary function and health-related quality of life J Clin Epidemiol 49 247-undefined

[77] Cazzola M(1998)Salmeterol xinafoate improves lung function and provides more symptom-free nights in chronic obstructive pulmonary disease (COPD) at marginal costs Thorax 53 558-undefined

[78] Cazzola M(1997)Economic evaluation of salmeterol xinafoate in chronic obstructive pulmonary disease (COPD) demonstrating improved outcomes and health status JAMA 277 246-undefined

[79] Matera MG(1994)A cost analysis of salmeterol xinafoate (Serevent) versus ipratropium bromide (Atrovent) for the treatment of COPD JAMA 272 1497-undefined

[80] Di Perna F(1992)Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients Chest 102 1384-undefined